ABO2109 and toripalimab
Phase 1
ABO2109 and toripalimab is one of 28 therapeutic programs targeting Non-small Cell Lung Cancer (NSCLC). It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
27
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
31 competitors in Non-Small Cell Lung Cancer (NSCLC)
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Imfinzi
AstraZenecaPhase 3
DATROWAY
Daiichi SankyoPhase 3
Paraplatin
AAvyxa
Phase 3
Alimta
GGynecologic Oncology Group
Phase 3
Taxotere
AAvyxa
Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Tylenol
KKenvue Brands
Phase 3
Pumitamig
Bristol-Myers SquibbPhase 3
Sacituzumab Tirumotecan
Merck & Co.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-small Cell Lung Cancer (NSCLC)1 trial
A Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacodynamic Characteristics, and Preliminary Anti-tumor Activity of Personalized Cancer Vaccine Alone and in Combination With Toripalimab in Patients With Resected NSCLC
Not yet recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 1·NCT07683832·50 enrolled
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for ABO2109 and toripalimab. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]